Investigators: Amy Baker, Dianne Sika-Paotonu, Joe Kado, Jonathan Carapetis, Rebecca Trowman, Robert Hand
Partner: Novartis Institute for BioMedical Research
The key objective of this study is to collect data about patient and clinician preferences about reformulations. By collection information from patients and parents of patients, manufacturers of a new form of long-acting penicillin can focus their efforts on changing aspects to improve patient adherence to secondary prophylaxis. For example, if more patients are concerned with having the penicillin last for longer than with reducing pain of injections, manufacturers can prioritize creating a longer-acting formulation, though attempts will be made to also reduce pain of injections. In addition, this study will collect preference information from clinicians and healthcare professionals, since these workers see multiple patients and can thus evaluate what would generally increase adherence for all of their patients. Using this information, we can target BPG reformulation efforts to ultimately increase adherence to secondary prophylaxis.